Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1992 Aug;68(2):171–175. doi: 10.1136/hrt.68.8.171

Streptokinase induced defibrination assessed by thrombin time: effects on residual coronary stenosis and left ventricular ejection fraction

Kulasegaram Ranjadayalan 1,2,3, Robert Stevenson 1,2,3, Bradley Marchant 1,2,3, Velaitham Umachandran 1,2,3, Simon W Davies 1,2,3, Denise Syndercombe-Court 1,2,3, Charles N Gutteridge 1,2,3, Adam D Timmis 1,2,3
PMCID: PMC1025008  PMID: 1389732

Abstract

Objective—To evaluate laboratory markers of defibrination early after thrombolytic therapy and to determine their relation to residual stenosis and left ventricular ejection fraction measured angiographically before discharge from hospital.

Design—Prospective analysis of defibrination after streptokinase measured by fibrinogen assay and thrombin time to provide a comparison of these coagulation variables for predicting angiographic responses to treatment in patients with acute myocardial infarction.

Setting—The coronary care unit of a district general hospital.

Patients—44 patients with acute myocardial infarction treated by streptokinase infusion, all of whom underwent paired blood sampling before and one hour after streptokinase and cardiac catheterisation at a median of six (interquartile range 3–9) days later.

Main outcome measures—Assay of thrombin time and plasma fibrinogen concentrations one hour after streptokinase infusion. Relations between these coagulation variables and residual stenosis in the infarct related coronary artery and left ventricular ejection fraction. Separate analyses are presented for all patients (n = 44) and those with patency of the infarct related artery (n = 35).

Results—Streptokinase infusion produced profound defibrination in every patient as shown by changes in thrombin time and circulating fibrinogen. Thrombin time after streptokinase infusion correlated significantly with both residual stenosis (r = −0·43, p < 0·005) and left ventricular ejection fraction (r = 0·38, p < 0·02). The importance of these correlations was emphasised by the interquartile group comparison which showed that a thrombin time ≥49 seconds predicted a residual stenosis of 74% and an ejection fraction of 65%, compared with 90% and 49% for a thrombin time ≤31 seconds (p < 0·01). When the analysis was restricted to patients with patency of the infarct related artery, the correlation between thrombin time and residual stenosis remained significant and group comparisons continued to show that patients in the highest quartile range had more widely patent arteries and better preservation of ejection fraction. Analysis of the fibrinogen data, on the other hand, showed insignificant or only marginally significant correlations with these angiographic variables.

Conclusions—Early after streptokinase infusion for acute myocardial infarction, the level of defibrination measured by thrombin time has an important influence on residual coronary stenosis and left ventricular ejection fraction at discharge from hospital, values above 49 seconds being associated with the best angiographic result.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnold A. E., Brower R. W., Collen D., van Es G. A., Lubsen J., Serruys P. W., Simoons M. L., Verstraete M. Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA. J Am Coll Cardiol. 1989 Sep;14(3):581–588. doi: 10.1016/0735-1097(89)90096-x. [DOI] [PubMed] [Google Scholar]
  2. Bell W. R., Meek A. G. Current concepts: guidelines for the use of thrombolytic agents. N Engl J Med. 1979 Dec 6;301(23):1266–1270. doi: 10.1056/NEJM197912063012305. [DOI] [PubMed] [Google Scholar]
  3. Brügemann J., van der Meer J., Takens B. H., Hillege H., Lie K. I. A systemic non-lytic state and local thrombolytic failure of anistreplase (anisoylated plasminogen streptokinase activator complex, APSAC) in acute myocardial infarction. Br Heart J. 1990 Dec;64(6):355–358. doi: 10.1136/hrt.64.6.355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. CLAUSS A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957 Apr;17(4):237–246. doi: 10.1159/000205234. [DOI] [PubMed] [Google Scholar]
  5. Chesebro J. H., Knatterud G., Roberts R., Borer J., Cohen L. S., Dalen J., Dodge H. T., Francis C. K., Hillis D., Ludbrook P. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987 Jul;76(1):142–154. doi: 10.1161/01.cir.76.1.142. [DOI] [PubMed] [Google Scholar]
  6. Davies S. W., Marchant B., Lyons J. P., Timmis A. D., Rothman M. T., Layton C. A., Balcon R. Coronary lesion morphology in acute myocardial infarction: demonstration of early remodeling after streptokinase treatment. J Am Coll Cardiol. 1990 Nov;16(5):1079–1086. doi: 10.1016/0735-1097(90)90535-w. [DOI] [PubMed] [Google Scholar]
  7. Feinstein A. R. T. Duckett Jones Memorial Lecture. The Jones criteria and the challenges of clinimetrics. Circulation. 1982 Jul;66(1):1–5. doi: 10.1161/01.cir.66.1.1. [DOI] [PubMed] [Google Scholar]
  8. Hochman J. S., Choo H. Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation. 1987 Jan;75(1):299–306. doi: 10.1161/01.cir.75.1.299. [DOI] [PubMed] [Google Scholar]
  9. Kennedy J. W., Ritchie J. L., Davis K. B., Stadius M. L., Maynard C., Fritz J. K. The western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. A 12-month follow-up report. N Engl J Med. 1985 Apr 25;312(17):1073–1078. doi: 10.1056/NEJM198504253121701. [DOI] [PubMed] [Google Scholar]
  10. Lew A. S., Cercek B., Hod H., Shah P. K., Ganz W. Usefulness of residual plasma fibrinogen after intravenous streptokinase for predicting delay or failure of reperfusion in acute myocardial infarction. Am J Cardiol. 1986 Oct 1;58(9):680–685. doi: 10.1016/0002-9149(86)90337-1. [DOI] [PubMed] [Google Scholar]
  11. Mukharji J., Rude R. E., Poole W. K., Gustafson N., Thomas L. J., Jr, Strauss H. W., Jaffe A. S., Muller J. E., Roberts R., Raabe D. S., Jr Risk factors for sudden death after acute myocardial infarction: two-year follow-up. Am J Cardiol. 1984 Jul 1;54(1):31–36. doi: 10.1016/0002-9149(84)90299-6. [DOI] [PubMed] [Google Scholar]
  12. O'Neill W., Timmis G. C., Bourdillon P. D., Lai P., Ganghadarhan V., Walton J., Jr, Ramos R., Laufer N., Gordon S., Schork M. A. A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. N Engl J Med. 1986 Mar 27;314(13):812–818. doi: 10.1056/NEJM198603273141303. [DOI] [PubMed] [Google Scholar]
  13. Sandler H., Dodge H. T. The use of single plane angiocardiograms for the calculation of left ventricular volume in man. Am Heart J. 1968 Mar;75(3):325–334. doi: 10.1016/0002-8703(68)90089-6. [DOI] [PubMed] [Google Scholar]
  14. Shafer K. E., Santoro S. A., Sobel B. E., Jaffe A. S. Monitoring activity of fibrinolytic agents. A therapeutic challenge. Am J Med. 1984 May;76(5):879–886. doi: 10.1016/0002-9343(84)91003-9. [DOI] [PubMed] [Google Scholar]
  15. Sharma G. V., Cella G., Parisi A. F., Sasahara A. A. Thrombolytic therapy. N Engl J Med. 1982 May 27;306(21):1268–1276. doi: 10.1056/NEJM198205273062105. [DOI] [PubMed] [Google Scholar]
  16. White C. W., Schwartz J. L., Ferguson D. W., Brayden G. P., Kelly K. J., Kioschos J. M., Marcus M. L. Systemic markers of fibrinolysis after unsuccessful intracoronary streptokinase thrombolysis for acute myocardial infarction. Does nonreperfusion indicate failure to achieve a systemic lytic state? Am J Cardiol. 1984 Oct 1;54(7):712–717. doi: 10.1016/s0002-9149(84)80195-2. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES